Markets News
Markets News

Fate Therapeutics (FATE) Receives a Hold from Wedbush

TipRanks
May. 14, 2025, 06:24 AM

Wedbush analyst David Nierengarten maintained a Hold rating on Fate Therapeutics (FATEResearch Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.00.

Confident Investing Starts Here:

Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, AnaptysBio, and Nuvation Bio. According to TipRanks, Nierengarten has an average return of 5.7% and a 40.33% success rate on recommended stocks.

In addition to Wedbush, Fate Therapeutics also received a Hold from Needham’s Gil Blum in a report issued today. However, on the same day, Barclays maintained a Buy rating on Fate Therapeutics (NASDAQ: FATE).

FATE market cap is currently $122.6M and has a P/E ratio of -0.61.

1.27
0.05 (4.10%)
Fate Therapeutics Inc
Find News News
OSZAR »